Best of 2025: Emerging therapies and techniques in corneal disease management
Our most-read cornea-focused coverage of 2025 highlights advances across both procedural and medical management of challenging corneal conditions. From refined cross-linking approaches for keratoconus to novel topical strategies aimed at reducing scarring and promoting epithelial healing, these articles reflect continued innovation in preserving corneal structure and visual outcomes.
Study shows both riboflavin types effective for keratoconus, with added benefit for thinner corneas
Both isoosmolar and hypoosmolar riboflavin formulations appear safe and effective for epithelium-off corneal cross-linking in progressive keratoconus, including eyes with thin corneas, according to a randomized clinical trial. While visual and tomographic outcomes were similar at 1 year, the hypoosmolar approach reduced the need for intraoperative corneal swelling, offering a potential procedural advantage without compromising safety.
Read the full article here.
hrDecorin Gel Eye Drops Reduce Corneal Scarring
A novel fluid gel eye drop delivering human recombinant decorin may represent a potential anti-scarring therapy for the cornea, according to preclinical research. In a mouse model, the formulation—designed to remain in prolonged contact with the ocular surface—reduced corneal scarring within days, with the hrDecorin fluid gel showing the greatest benefit, highlighting a possible non-surgical approach to managing corneal scarring.
Read the full article here.
Topical insulin shows promise for persistent epithelial defects
Topical insulin may offer a promising approach for managing persistent corneal epithelial defects, delivering high rates of complete wound healing with a low risk of failure, according to a pooled analysis. Across 13 studies, most eyes achieved epithelial closure within weeks, and patients treated with topical insulin were significantly more likely to heal than controls.
Read the full article here.
Related Content
